Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452380 | 0.79 | HRH3 (0.42) | — | |
| SCHEMBL4368233 | 0.79 | FDPS (0.40) | FDPS | |
| SCHEMBL6539479 | 0.76 | KCNH2 (0.39) | — | |
| SCHEMBL5789735 | 0.76 | SIGMAR1 (0.47) | — | |
| SCHEMBL20462627 | 0.74 | DNM1 (0.37) | FDPS | |
| SCHEMBL6539573 | 0.73 | L3MBTL1 (0.41) | — | |
| SCHEMBL19942664 | 0.72 | FDPS (0.35) | FDPS | |
| SCHEMBL21140634 | 0.72 | FDPS (0.35) | FDPS | |
| SCHEMBL6539704 | 0.71 | KCNH2 (0.39) | — | |
| SCHEMBL15996340 | 0.70 | FDPS (0.35) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082757-A1 | Echinocandin derivatives, pharmaceutical compositions containing same and use thereof as drugs | ASTELLAS PHARMA INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1366065-A1 | ECHINOCANDIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF AS DRUGS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002068456-A1 | ECHINOCANDIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF AS DRUGS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-06 | — | — | WO | disclosed |
| US-6232290-B1 | FUNGICIDES AGAINST PNEUMOCYSTIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| EP-1053247-A1 | ANTIFUNGAL CYCLOHEXAPEPTIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040108-A1 | NEW COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082757-A1 | Echinocandin derivatives, pharmaceutical compositions containing same and use thereof as drugs | MAN2B1, MAN2A1, ALG1 | FDPS 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.